JP2004508339A5 - - Google Patents

Download PDF

Info

Publication number
JP2004508339A5
JP2004508339A5 JP2002524528A JP2002524528A JP2004508339A5 JP 2004508339 A5 JP2004508339 A5 JP 2004508339A5 JP 2002524528 A JP2002524528 A JP 2002524528A JP 2002524528 A JP2002524528 A JP 2002524528A JP 2004508339 A5 JP2004508339 A5 JP 2004508339A5
Authority
JP
Japan
Prior art keywords
vaccine
composition
gene
heat shock
stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002524528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508339A (ja
Filing date
Publication date
Priority claimed from GBGB0021757.0A external-priority patent/GB0021757D0/en
Application filed filed Critical
Publication of JP2004508339A publication Critical patent/JP2004508339A/ja
Publication of JP2004508339A5 publication Critical patent/JP2004508339A5/ja
Pending legal-status Critical Current

Links

JP2002524528A 2000-09-04 2001-09-04 微生物病原体ワクチン Pending JP2004508339A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021757.0A GB0021757D0 (en) 2000-09-04 2000-09-04 Vaccine against microbial pathogens
PCT/GB2001/003964 WO2002020045A2 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens

Publications (2)

Publication Number Publication Date
JP2004508339A JP2004508339A (ja) 2004-03-18
JP2004508339A5 true JP2004508339A5 (enExample) 2008-10-16

Family

ID=9898866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002524528A Pending JP2004508339A (ja) 2000-09-04 2001-09-04 微生物病原体ワクチン

Country Status (15)

Country Link
US (1) US20050232946A1 (enExample)
EP (1) EP1315518B1 (enExample)
JP (1) JP2004508339A (enExample)
CN (1) CN1452495A (enExample)
AT (1) ATE450270T1 (enExample)
AU (1) AU2001284261A1 (enExample)
CA (1) CA2421229A1 (enExample)
DE (1) DE60140681D1 (enExample)
DK (1) DK1315518T3 (enExample)
ES (1) ES2337653T3 (enExample)
GB (1) GB0021757D0 (enExample)
IL (1) IL154727A0 (enExample)
PT (1) PT1315518E (enExample)
WO (1) WO2002020045A2 (enExample)
ZA (1) ZA200301759B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1791811E (pt) * 2004-09-21 2010-02-23 Astellas Pharma Inc ¿derivados de aminoálcool
CN101522213A (zh) 2006-09-01 2009-09-02 Csl有限公司 引起或诱导免疫应答的方法
WO2009021291A1 (en) * 2007-08-16 2009-02-19 The University Of Sydney Mycobacterium vaccine formulation
SG185294A1 (en) 2007-10-12 2012-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
GB0910591D0 (en) 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
GB201104897D0 (en) 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same
CA2833633A1 (en) * 2011-04-20 2012-10-26 Jason Fisher Composition and method for enhancing an immune response

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3752263T2 (de) * 1986-08-18 1999-07-08 Btg International Ltd., London Impfstoffe
US5776724A (en) * 1988-10-24 1998-07-07 Yale University Chaperonin-mediated protein folding
JPH03204820A (ja) * 1989-10-12 1991-09-06 Nippon Saibai Suisan Kk エビ類の細菌性疾病予防ワクチン及びその製造法
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
JPH08509873A (ja) * 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
JPH0748398A (ja) * 1993-08-03 1995-02-21 Nippon Oil Co Ltd 変性蛋白質の再生方法及び変性蛋白質再生剤
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
US6872542B1 (en) * 1993-11-18 2005-03-29 Siga Pharmaceuticals, Inc. Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CZ394297A3 (cs) * 1995-06-07 1998-04-15 Biochem Vaccines Inc. Streptokokové proteiny teplotního šoku ze skupiny HSP70
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
JP2000502054A (ja) * 1995-11-30 2000-02-22 アグリカルチャー ビクトリア サービシーズ ピーティーワイ.エルティーディー. 治療用および診断用の組成物
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
EP0950061A4 (en) * 1996-09-20 2000-04-12 Univ New Mexico Heat shock protein complexes
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6500434B1 (en) * 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU770498B2 (en) * 1998-06-19 2004-02-26 Merieux Oravax LT and CT in parenteral immunization methods against helicobacter infection
GB9818133D0 (en) * 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
CA2363146A1 (en) * 1999-02-22 2000-08-31 Solomon Langermann Caulobacter lps immunoadjuvant
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
GB9919734D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
US6677139B1 (en) * 1999-12-23 2004-01-13 Genecor International, Inc. Methods for production of proteins in host cells
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
WO2001079259A1 (en) * 2000-04-17 2001-10-25 Rothman James E Javelinization of protein antigens to heat shock proteins
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
US6932985B2 (en) * 2000-10-10 2005-08-23 Auburn University Azide method and composition for controlling deleterious organisms
WO2002059156A2 (en) * 2000-12-22 2002-08-01 Medimmune, Inc. Therapeutic compounds structurally-linked to bacterial polypeptides
AU2003216288B2 (en) * 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
WO2003074003A2 (en) * 2002-03-01 2003-09-12 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
CA2483925A1 (en) * 2002-05-02 2004-04-29 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines comprising heat shock protein-peptide complexes or alpha-2-macroglobulin-peptide complexes

Similar Documents

Publication Publication Date Title
Yadav et al. Vaccines: present status and applications
Jorge et al. The development of veterinary vaccines: a review of traditional methods and modern biotechnology approaches
Strugnell et al. Vaccine antigens
Silin et al. Oral vaccination: where we are?
O’Hagan Oral delivery of vaccines: formulation and clinical pharmacokinetic considerations
Boutier et al. Current knowledge and future prospects of vaccines against cyprinid herpesvirus 3 (CyHV-3)
Plotkin Six revolutions in vaccinology
JP2004536106A5 (enExample)
Bonanni et al. Vaccine evolution
Simerska et al. Oral vaccine delivery-new strategies and technologies
CN101914564B (zh) 一种大肠杆菌多个肠毒素基因的融合体及其应用
JP2004508339A (ja) 微生物病原体ワクチン
CA2382336C (en) Vaccines from infectious agents
Wan et al. Immunogenic analysis of two DNA vaccines of avian reovirus mediated by attenuated Salmonella typhimurium in chickens
Kumar et al. Whole-cell vaccine preparation: Options and perspectives
Gupta et al. Role of microbes in production of vaccines
Navruzshoeva et al. Current trends in increasing the biological activity of vaccine strains of Bacillus anthracic
Sabbaj et al. Mucosal immunisation for enteric diseases: Current practice and future prospects
Lina Efficiency Evaluation of 5BT, a Genetically Recombinant Multi-epitope-protein, for Its Application as a Subunit Vaccine against Foot and Mouth Disease
Khatri Therapeutic DNA Vaccines:“Future strategies”
Parnham opments in vaccinology will be outlined.
Peters et al. Oral Vaccination: Attenuated and Gene-Based
Massabni et al. Biotechnology and vaccines
Ellis New technologies for bacterial vaccines
Brown From jenner to genes—The next generation of virus vaccines